WellStar Research Insititute
Welcome,         Profile    Billing    Logout  
 1 Trial 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
McLaughlin, Mark
MTI201-IA, NCT05496686: Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

Recruiting
1
16
US
4.7 microCi 225Ac-MTI-201, 4.7 microCi 225Actinium-MTI-201, 9.5 microCi of 225Ac-MTI-201, 9.5 microCi 225Actinium-MTI-201, 19 microCi of 225Ac-MTI-201, 19 microCi 225Actinium-MTI-201, 38 microCi of 225Ac-MTI-201, 38 microCi 225Actinium-MTI-201, 76 microCi of 225Ac-MTI-201, 76 microCi 225Actinium-MTI-201, 152 microCi of 225Ac-MTI-201, 152 microCi 225Actinium-MTI-201, 254 microCi of 225Ac-MTI-201, 254 microCi 225Actinium-MTI-201, 424 microCi of 225Ac-MTI-201, 424 microCi 225Actinium-MTI-201, 564 microCi of 225Ac-MTI-201, 564 microCi 225Actinium-MTI-201, 750 microCi of 225Ac-MTI-201, 750 microCi 225Actinium-MTI-201, 998 microCi of 225Ac-MTI-201, 998 microCi 225Actinium-MTI-201, 1327 microCi of 225Ac-MTI-201, 1327 microCi 225Actinium-MTI-201
Modulation Therapeutics, Inc., H. Lee Moffitt Cancer Center and Research Institute
Uveal Melanoma, Metastatic
04/25
02/29

Download Options